As economic and regulatory uncertainty loom over the 2025 TV upfronts, pharma marketers are rethinking how they show up across media. In Sam Bradley’s latest piece for Digiday, our EVP…
BranchLab CEO, Josh Walsh, weighs in on the role state regulations will play for marketers, especially pharma advertisers, in the vacuum of federal regulation.
The advertising landscape is changing, especially for healthcare and pharmaceutical companies. This January, the New York Senate approved S929 – a groundbreaking data privacy law and significant step towards greater…
BranchLab’s Michael Parkes predicts: “State privacy regulations, such as Washington’s My Health My Data Act, will profoundly reshape pharmaceutical advertising by imposing strict limitations on the use of health data….
BranchLab’s Michael Parkes provides an overview of the emerging state regulations impacting the media strategies of pharmaceutical and healthcare brands, offering recommendations on how to navigate a new era of…
BranchLab CEO, Josh Walsh, weighs in on Meta’s move to implement stricter policies for health and wellness brands.
August 19, 2024 – New York, NY: BranchLab has appointed Errol Taylor to its Board of Advisors to help guide the newly launched company on its mission to reimagine healthcare…
As a part of the MediaPost webinar series, we joined a session hosted by Causal IQ to discuss Healthcare Professionals (HCPs) and how to best reach & market to them…
In Partnership with BranchLab, Causal IQ Introduces a Revolutionary Privacy-Focused Approach to Healthcare Advertising July 18, 2024 – LOS ANGELES – Causal IQ, a leading provider of advanced digital advertising…
